Sodium–glucose cotransporter-2 (SGLT2) inhibitors are widely used not only for patients with diabetes mellitus (DM) but also for patients with congestive heart failure (CHF) and chronic kidney disease (CKD) regardless of DM status. Here, SLC5A2 is linked to congestive heart failure.